QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)

Petros Pharmaceuticals (PTPI) Competitors

$1.59
+0.03 (+1.92%)
(As of 02/21/2024 ET)

PTPI vs. FWBI, PRFX, PHAS, ARDS, ADXS, SNPX, AGRX, ONCO, AIMD, and CPHI

Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include First Wave BioPharma (FWBI), PainReform (PRFX), PhaseBio Pharmaceuticals (PHAS), Aridis Pharmaceuticals (ARDS), Ayala Pharmaceuticals (ADXS), Synaptogenix (SNPX), Agile Therapeutics (AGRX), Onconetix (ONCO), Ainos (AIMD), and China Pharma (CPHI). These companies are all part of the "pharmaceutical preparations" industry.

Petros Pharmaceuticals vs.

First Wave BioPharma (NASDAQ:FWBI) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

First Wave BioPharma has a net margin of 0.00% compared to First Wave BioPharma's net margin of -181.87%. First Wave BioPharma's return on equity of -97.67% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
First Wave BioPharmaN/A -652.25% -295.45%
Petros Pharmaceuticals -181.87%-97.67%-38.90%

First Wave BioPharma received 8 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 45.00% of users gave First Wave BioPharma an outperform vote.

CompanyUnderperformOutperform
First Wave BioPharmaOutperform Votes
9
45.00%
Underperform Votes
11
55.00%
Petros PharmaceuticalsOutperform Votes
1
100.00%
Underperform Votes
No Votes

First Wave BioPharma currently has a consensus target price of $120.00, suggesting a potential upside of 2,319.35%. Petros Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 151.57%. Given Petros Pharmaceuticals' higher possible upside, research analysts clearly believe First Wave BioPharma is more favorable than Petros Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Wave BioPharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

First Wave BioPharma has higher earnings, but lower revenue than Petros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Wave BioPharmaN/AN/A-$14.63M-$272.80-0.02
Petros Pharmaceuticals$5.99M0.58-$20.04MN/AN/A

First Wave BioPharma has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

In the previous week, First Wave BioPharma's average media sentiment score of 0.72 beat Petros Pharmaceuticals' score of 0.00 indicating that Petros Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
First Wave BioPharma Neutral
Petros Pharmaceuticals Positive

2.5% of First Wave BioPharma shares are held by institutional investors. Comparatively, 4.9% of Petros Pharmaceuticals shares are held by institutional investors. 0.5% of First Wave BioPharma shares are held by company insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Petros Pharmaceuticals beats First Wave BioPharma on 9 of the 13 factors compared between the two stocks.


Get Petros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTPI vs. The Competition

MetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.50M$6.68B$4.98B$7.34B
Dividend YieldN/A2.75%2.92%3.85%
P/E RatioN/A18.21119.8318.18
Price / Sales0.58140.432,973.1057.77
Price / CashN/A18.5091.0754.06
Price / Book0.204.424.304.56
Net Income-$20.04M$156.98M$112.67M$207.35M
7 Day Performance-0.63%1.37%1.64%0.64%
1 Month Performance31.40%9.95%7.21%4.52%
1 Year Performance-34.57%-0.88%7.09%3.76%

Petros Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FWBI
First Wave BioPharma
1.2997 of 5 stars
$4.99
-9.1%
$120.00
+2,304.8%
-93.4%$3.39MN/A-0.0210
PRFX
PainReform
0 of 5 stars
$2.11
-2.3%
N/A-67.3%$3.29MN/A0.006Gap Up
PHAS
PhaseBio Pharmaceuticals
0 of 5 stars
N/AN/AN/A$3.50M$818,000.00-0.0360
ARDS
Aridis Pharmaceuticals
0.4605 of 5 stars
$0.07
flat
$2.00
+2,621.1%
-87.2%$3.52M$3.09M-0.4637Gap Up
ADXS
Ayala Pharmaceuticals
0 of 5 stars
$0.67
-27.2%
N/A-53.6%$3.24M$3.24M0.00N/AUpcoming Earnings
Analyst Report
News Coverage
High Trading Volume
SNPX
Synaptogenix
0 of 5 stars
$0.16
-5.9%
N/A-83.4%$3.23MN/A-0.155Positive News
Gap Down
AGRX
Agile Therapeutics
3.4949 of 5 stars
$1.20
+0.8%
$8.50
+608.3%
+295.9%$3.55M$10.88M-0.0922News Coverage
ONCO
Onconetix
0 of 5 stars
$0.17
+6.2%
N/AN/A$3.21MN/A-0.1612News Coverage
Gap Up
AIMD
Ainos
0 of 5 stars
$0.90
-5.3%
N/AN/A$3.65M$3.52M-0.3543Positive News
Gap Down
CPHI
China Pharma
0 of 5 stars
$0.09
flat
N/AN/A$3.01M$8.10M0.00234Gap Down

Related Companies and Tools

This page (NASDAQ:PTPI) was last updated on 2/21/2024 by MarketBeat.com Staff